retatrutide lilly Seeking Differentiation Through a Triple Mechanism" Eli Lilly's Again Proves Efficacy in Trials, Raising Question of Whether It Can Overcome Side-Effect Limits and Reshape the Market Doctor Comment: Eli Lilly Drug

This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD [chronic kidney disease], said lead author Sunil Badve, professorial fellow at The George Institute for Global Health and UNSW Sydney

This drug is positioned as a potential breakthrough in obesity treatment

Unger', The Journal of Clinical Investigation

Jessica Reilly, who serves as the medical director at Strong4Life pediatric obesity clinic at Childrens Healthcare of Atlanta, says shes treated kids with obesity who have developed Type 2 diabetes at 10, 11 years old, explaining that these kids need help so desperately. Yes, there are intensive behavioral treatment programs for kids with obesity